Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arcadia Biosciences (RKDA) EBT (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed EBT for 12 consecutive years, with -$1.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT rose 2.37% year-over-year to -$1.2 million, compared with a TTM value of -$5.2 million through Sep 2025, down 216.37%, and an annual FY2024 reading of -$4.3 million, up 19.02% over the prior year.
  • EBT was -$1.2 million for Q3 2025 at Arcadia Biosciences, down from -$501000.0 in the prior quarter.
  • Across five years, EBT topped out at $5.2 million in Q4 2023 and bottomed at -$16.1 million in Q4 2021.
  • Average EBT over 5 years is -$2.8 million, with a median of -$1.6 million recorded in 2024.
  • The sharpest move saw EBT plummeted 289.99% in 2021, then surged 610.76% in 2023.
  • Year by year, EBT stood at -$16.1 million in 2021, then surged by 93.64% to -$1.0 million in 2022, then soared by 610.76% to $5.2 million in 2023, then crashed by 177.2% to -$4.0 million in 2024, then surged by 71.36% to -$1.2 million in 2025.
  • Business Quant data shows EBT for RKDA at -$1.2 million in Q3 2025, -$501000.0 in Q2 2025, and $530000.0 in Q1 2025.